Business

OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products.… Read more . . .

InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company’s inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No.… Read more . . .

Celdara Medical and Pulmatrix have been awarded a 3-year $1.7 million Fast Track Small Business Innovation Research grant from the National Heart Lung and Blood Institute (NHLBI) for development of an inhaled therapy for the… Read more . . .

GlaxoSmithKline has exercised an option for an exclusive license to develop inhaled therapies using Liquidia Techonologies’ PRINT particle engineering technology, Liquidia said. The option was included in a collaboration deal the two companies signed in… Read more . . .

Teva Pharmaceutical has acquired privately held Gecko Health Innovations and its CareTRx asthma and COPD management system. CareTRx works with a monitoring device called GeckoCap that attaches to an MDI plus a mobile phone app.… Read more . . .

Inhaled drug developer Alexza Pharmaceuticals has hired a financial advisor “to assist in exploring strategic options to enhance stockholder value,” the company said. Options being explored include selling corporate assets, a strategic business combination, or… Read more . . .

Natesto intranasal testosterone developer Trimel Pharmaceuticals Corporation has announced that it has a new name: Acerus Pharmaceuticals Corporation. Acerus President and CEO Tom Rossi commented, “We are very excited to officially launch our new corporate… Read more . . .

Invion Limited, which is developing several inhaled drugs, has announced a private placement in which it is issuing 71.5 million ordinary shares at $0.014 per share to “a US institutional investor” for a total of… Read more . . .

Aegis Therapeutics has announced that it received its first Russian patent (No. 2554814), titled, “Compositions for drug administration.” The patent covers formulations of triptans for the treatment of migraine that use Aegis’ Intravail transmucosal absorption… Read more . . .

Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT), which recently received orphan drug status in Europe for its inhaled nitric oxide for the treatment of cystic fibrosis, has filed with the US Securities and Exchange Commission… Read more . . .